<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576524</url>
  </required_header>
  <id_info>
    <org_study_id>2007-12-5712</org_study_id>
    <nct_id>NCT00576524</nct_id>
  </id_info>
  <brief_title>Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis</brief_title>
  <acronym>ITD</acronym>
  <official_title>Application of Impedance Threshold Device Technologies to Treat and Prevent Intradialytic Hypotension in Children Undergoing Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advanced Circulatory Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the application of the impedance threshold device
      during hemodialysis in children to optimize fluid removal, reduce the incidence of
      complications (such as cramps,vomiting and hypotension), and device tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Effective fluid removal during hemodialysis is one of the biggest challenges in children with
      end-stage renal disease (ESRD). Generally, children do not tolerate having more than 3-4% of
      their body weight removed during each dialysis session thus necessitating multiple sessions
      each week to ensure effective renal replacement. Excessive fluid removal is often associated
      with nausea, vomiting, hypotension and cramps resulting in serious complications in patient
      care during and immediately after dialysis as well as reduced patient compliance. The
      development of novel therapies to increase the amount of fluid removed during each session
      without a corresponding increase in the incidence of complications is therefore very
      important to improve quality and compliance with hemodialysis; and eventually survival of
      children with ESRD. The purpose of this study is to evaluate the application of the impedance
      threshold device during hemodialysis in children to optimize fluid removal, reduce the
      incidence of complications (such as cramps,vomiting and hypotension), and device tolerance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Completion not feasible. THERE ARE NO RESULTS FROM THIS TRIAL
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluid Removal</measure>
    <time_frame>6 weeks</time_frame>
    <description>Fluid removed as percentage of dry body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extra Days to Achieve Target Dry Weight</measure>
    <time_frame>6 weeks</time_frame>
    <description>Extra number of days required for hemodialysis/ultrafiltration to achieve dry body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Heart Rate and Blood Pressure Measured by a Non-invasive Cuff.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Intradialytic Hypotension</condition>
  <condition>End Stage Renal Disease</condition>
  <condition>Low Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Sham Device first, ITD next</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITD first, sham device next</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ITD</intervention_name>
    <description>ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions</description>
    <arm_group_label>Sham Device first, ITD next</arm_group_label>
    <arm_group_label>ITD first, sham device next</arm_group_label>
    <other_name>ResQpod</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions</description>
    <arm_group_label>Sham Device first, ITD next</arm_group_label>
    <arm_group_label>ITD first, sham device next</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 8-18 years of age

          -  Subjects undergoing hemodialysis for ESRD

        Exclusion Criteria:

          -  Subjects less than 8 years old or greater than 18 years old.

          -  Hemodialysis for indications other than ESRD.

          -  Current symptoms of chest pain, shortness of breath, fever, presence of dilated
             cardiomyopathy, unstable congestive heart failure, pulmonary hypertension, atrial
             fibrillation, hyperthyroidism, and aortic stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Srinivasan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2007</study_first_submitted>
  <study_first_submitted_qc>December 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>December 12, 2012</results_first_submitted>
  <results_first_submitted_qc>January 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2013</results_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Vijay Srinivasan</investigator_full_name>
    <investigator_title>Attending Physician</investigator_title>
  </responsible_party>
  <keyword>Hypotension during dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Decrease complications during dialysis</keyword>
  <keyword>Low Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study recruited subjects from September 2007 to February 2011. The study will be performed in the Dialysis Unit of the Division of Nephrology, Department of Pediatrics at the Children’s Hospital of Philadelphia (CHOP) with informed consent.</recruitment_details>
      <pre_assignment_details>The study design will consist of a “run-in phase”, followed by a randomized, cross-over, clinical “intervention phase” with application of the ITD (sham or -7 cm H2O) in 20 pediatric subjects undergoing regular hemodialysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ITD First, Sham Device Next</title>
          <description>A group of subjects will be randomized to receive the ITD first, followed by sham 7 days later.</description>
        </group>
        <group group_id="P2">
          <title>Sham Device First, ITD Next</title>
          <description>A group of subjects will be randomized to receive sham first, followed by ITD 7 days later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham Device</title>
          <description>A group of subjects will be randomized to receive the placebo sham device.</description>
        </group>
        <group group_id="B2">
          <title>ITD Device</title>
          <description>A group of subjects will be randomized to receive Impedance Threshold Device.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not analyzed- study closed due to lack of recruitment</measurement>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data not analyzed- study closed due to lack of recruitment</measurement>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fluid Removal</title>
        <description>Fluid removed as percentage of dry body weight.</description>
        <time_frame>6 weeks</time_frame>
        <population>Data not analyzed - study closed due to lack of recruitment</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Device First, ITD Next</title>
            <description>A group of subjects will be randomized to receive the sham device, followed by ITD next after 7 days.</description>
          </group>
          <group group_id="O2">
            <title>ITD First, Sham Device Next</title>
            <description>A group of subjects will be randomized to receive ITD, followed by sham device after 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Removal</title>
          <description>Fluid removed as percentage of dry body weight.</description>
          <population>Data not analyzed - study closed due to lack of recruitment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extra Days to Achieve Target Dry Weight</title>
        <description>Extra number of days required for hemodialysis/ultrafiltration to achieve dry body weight</description>
        <time_frame>6 weeks</time_frame>
        <population>Data not analyzed - study closed due to lack of recruitment</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Device First, ITD Next</title>
            <description>A group of subjects will be randomized to receive the sham device, follwed by ITD 7 days later.</description>
          </group>
          <group group_id="O2">
            <title>ITD First, Sham Device Next</title>
            <description>A group of subjects will be randomized to receive ITD, followed by sham device 7 days later.</description>
          </group>
        </group_list>
        <measure>
          <title>Extra Days to Achieve Target Dry Weight</title>
          <description>Extra number of days required for hemodialysis/ultrafiltration to achieve dry body weight</description>
          <population>Data not analyzed - study closed due to lack of recruitment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Heart Rate and Blood Pressure Measured by a Non-invasive Cuff.</title>
        <time_frame>6 weeks</time_frame>
        <population>Data not analyzed - study closed due to lack of recruitment</population>
        <group_list>
          <group group_id="O1">
            <title>Sham Device</title>
            <description>A group of subjects will be randomized to receive the placebo sham device.</description>
          </group>
          <group group_id="O2">
            <title>ITD Device</title>
            <description>A group of subjects will be randomized to receive Impedance Threshold Device.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Heart Rate and Blood Pressure Measured by a Non-invasive Cuff.</title>
          <population>Data not analyzed - study closed due to lack of recruitment</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sham Device</title>
          <description>A group of subjects will be randomized to receive the placebo sham device.</description>
        </group>
        <group group_id="E2">
          <title>ITD Device</title>
          <description>A group of subjects will be randomized to receive Impedance Threshold Device.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marsha Wallace</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>(215) 590-0119</phone>
      <email>wallacem@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

